Michael Baria, MD MBA’s Post

Leukocytes Do Not Influence the Safety and Efficacy of Platelet-Rich Plasma Injections for the Treatment of Knee Osteoarthritis This double-blind RCT of 132 patients investigated the impact of leukocyte concentration on PRP outcomes in knee OA treatment. Key findings: No significant differences in clinical outcomes between LR-PRP and LP-PRP Comparable improvements in pain and function between groups Similar adverse event rates and treatment failures Results challenge assumptions about negative effects of leukocytes The study suggests that leukocyte concentration may be less important than other factors in PRP preparation for knee OA treatment. Clinical Perspective: It's important to note that the leukocyte concentration difference between the two treatment groups in this study was relatively modest. Most commercial systems produce LR-PRP with approximately 4x baseline leukocyte concentration, which typically results in higher adverse event rates than those observed in this study. This distinction should be considered when interpreting these results in clinical practice. ACCESS HERE: https://lnkd.in/gfKxphmx #mdbiologix #PRP #leukocytes #research

"Care ... & ... Aware" One of the rare complication of hyperthyroidism is “Thyroid-associated ophthalmopathy” (TAO) or “Graves' ophthalmopathy”, which is a complex disease attributed to the presence of TSH receptors and insulin-like growth factor 1 receptor (IGF-1R) in orbital fibrocytes. Although severe TAO is rare, it is difficult to treat. A 15-20% risk of aggravating severe eye disease may occur following radioactive iodine RAI, especially in those who smoke. Management requires effective treatment of the thyroid disease, usually by total surgical excision or iodine-131 (131-I) ablation of the gland pus anti-inflammatory therapies. Treatment and management: - Elevation of the head to diminish periorbital edema - Artificial tears to relieve corneal drying due to exophthlmos - Smoking cessation to prevent progression of the ophthalmopathy - For severe and acute inflammatory reaction: prednisone 60-100 mg orally daily for about a week, then 60-100 mg every other day, tapering the dose over 6-12 weeks - Teprotumumab (Tepezza), a monoclonal antibody given once every 3 weeks for total of 8 IV infusions, significantly reduces eye bulges, pain and swelling, and double vision - If the aforementioned therapy fails or is contraindicated, irradiation of the posterior orbit, using well-collimated high-energy X-ray therapy, will frequently result in marked improvement of the acute process - Threatened loss of vision is an indication for surgical decompression of the orbit. Eye-lid or eye muscle surgery may be necessary to correct residual problems after the acute process has subsided References: - Katzung's basic & clinical pharmacology, 16th edition #thyroid_associated_ophthalmopathy #insulin_like_growth_factor_1 #teprotumumab #hyperthyroidism #drug_information_76 #clinical_pharmacology #pharmacy_review #counseling_points #patient_education

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS – Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks – – The twice-yearly, 10-minute SC injection has the potential to expand the usage of Ocrevus to treatment centers without IV infrastructure or with IV capacity limitations – – U.S. FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024 – “Updated results from OCARINA II further underline the potential benefits of subcutaneous Ocrevus for patients with both relapsing and progressive forms of MS,” said Scott Newsome, D.O., lead author, Johns Hopkins University School of Medicine. “Patients treated with subcutaneous Ocrevus experienced appropriate B-cell suppression and impressive near-complete suppression of new inflammatory disease activity. These results demonstrate the potential of subcutaneous Ocrevus as a treatment option that can be matched to the individual needs of people with MS and healthcare professionals.” Additional data continued to show that the safety profile of Ocrevus SC injection was consistent with the well-established safety profile of Ocrevus IV infusion. No new safety signals were identified for Ocrevus SC. The most common adverse events in the Ocrevus SC group were injection reactions (51.5% of all exposed patients), including erythema (34.8%; skin redness or irritation), pain (17.2%), swelling (9.4%) and pruritus (5.6%; skin itching), all of which were either mild or moderate and none of which led to treatment withdrawal. A total of seven serious AEs were experienced by three (2.6%) and four (3.4%) patients in the Ocrevus SC injection and IV infusion groups, respectively. The OCARINA II abstract was selected as an abstract of distinction by the AAN, based on the quality of the study and the interest to the neurology community. https://lnkd.in/eShr75YM

📃Scientific paper: The use of tamsulosin in the treatment of 10–15 mm lower ureteral stones in adults: a double-blinded randomized controlled trial Abstract: Background The discovery of alpha-adrenergic receptors in the ureteral smooth muscle cells led to a thorough investigation of the therapeutic potential of alpha-blockers for ureteral calculi. Tamsulosin is a selective blocker of alpha-1A and alpha-1B adrenoceptors. It significantly improved the expulsion of distal ureteral stones measuring 3–10 mm in most randomized trials. To the best of our knowledge, tamsulosin was not tested before in the management of ureteral stones 10–15 mm. Hence, the present study aimed at estimation of the efficacy of tamsulosin in the expulsion of lower ureteral stones 10–15 mm in length compared to placebo in adult patients (primary goal) and the need for ureteral dilatation at scheduled ureteroscopy. Methods Between November 2017 and November 2019, 80 patients with distal ureteral stones 10–15 mm were divided into two equal groups. One group received tamsulosin 0.4 mg/day and the other received a placebo. Patients were followed-up for 8 weeks. Results Six patients of the tamsulosin group (15%) passed their stones spontaneously compared to none of the placebo group ( p  = 0.026). Two of the 6 patients who passed the ureteral stones developed urinary retention and required endoscopic treatment of urethral stones. So, the adjusted spontaneous ureteral stone passage ratios for the tamsulosin and the control groups were 10 and 0%, respectively ( p  = 0.12). Overall, 37.5% reported adverse effects in the tamsulosin group, and 30% in the pl... Continued on ES/IODE ➡️ https://etcse.fr/51Q6q ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Endovascular Treatment of Cavernous Sinus Dural Arteriovenous Fistulas. Institutional Series, Systematic Review and Meta-Analysis Abstract: Purpose Endovascular treatment represents the first-line therapy for cavernous sinus dural arteriovenous fistulas (CS-dAVF); however, different approaches and embolic agents as well as occlusion rates, complications and clinical outcomes are reported among the published series. In this study we performed a comprehensive meta-analysis to investigate clinical and radiological outcomes after endovascular treatment of CS-dAVFs. Methods PubMed, Ovid Medline, Ovid EMBASE, Scopus, and Web of Science were screened for a comprehensive literature review from 1990 to 2020 regarding series of patients treated for CS-dAVF with endovascular approaches. We performed a proportion meta-analysis estimating the pooled rates of each outcome also including data of patients treated in our center. Results A total of 22 studies reporting 1043 patients and 1066 procedures were included. Chemosis was reported in 559 out of 1043 patients (45.9%), proptosis in 498 (41.5%), and ophthalmoplegia in 344 (23.5%). A transvenous embolization was preferred in 753 cases (63.2%) and coils were used in 712 out of 1066 procedures (57.8%). Overall, 85% (95% confidence interval, CI 69.5–96.1%) of patients had a complete resolution of symptoms, while complications occurred in 7.75% (95% CI 3.82–12.7%) with minimal permanent deficits (0.15%). The mortality rate was 1 out of 1043 patients (< 0.001). Conclusion A transvenous coiling is the most common endovascular approach for CS-dAVF, achieving a high percent... Continued on ES/IODE ➡️ https://etcse.fr/5mzv ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Endovascular Treatment of Cavernous Sinus Dural Arteriovenous Fistulas. Institutional Series, Systematic Review and Meta-Analysis Abstract: Purpose Endovascular treatment represents the first-line therapy for cavernous sinus dural arteriovenous fistulas (CS-dAVF); however, different approaches and embolic agents as well as occlusion rates, complications and clinical outcomes are reported among the published series. In this study we performed a comprehensive meta-analysis to investigate clinical and radiological outcomes after endovascular treatment of CS-dAVFs. Methods PubMed, Ovid Medline, Ovid EMBASE, Scopus, and Web of Science were screened for a comprehensive literature review from 1990 to 2020 regarding series of patients treated for CS-dAVF with endovascular approaches. We performed a proportion meta-analysis estimating the pooled rates of each outcome also including data of patients treated in our center. Results A total of 22 studies reporting 1043 patients and 1066 procedures were included. Chemosis was reported in 559 out of 1043 patients (45.9%), proptosis in 498 (41.5%), and ophthalmoplegia in 344 (23.5%). A transvenous embolization was preferred in 753 cases (63.2%) and coils were used in 712 out of 1066 procedures (57.8%). Overall, 85% (95% confidence interval, CI 69.5–96.1%) of patients had a complete resolution of symptoms, while complications occurred in 7.75% (95% CI 3.82–12.7%) with minimal permanent deficits (0.15%). The mortality rate was 1 out of 1043 patients (< 0.001). Conclusion A transvenous coiling is the most common endovascular approach for CS-dAVF, achieving a high percent... Continued on ES/IODE ➡️ https://etcse.fr/5mzv ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Endovascular Treatment of Cavernous Sinus Dural Arteriovenous Fistulas. Institutional Series, Systematic Review and Meta-Analysis Abstract: Purpose Endovascular treatment represents the first-line therapy for cavernous sinus dural arteriovenous fistulas (CS-dAVF); however, different approaches and embolic agents as well as occlusion rates, complications and clinical outcomes are reported among the published series. In this study we performed a comprehensive meta-analysis to investigate clinical and radiological outcomes after endovascular treatment of CS-dAVFs. Methods PubMed, Ovid Medline, Ovid EMBASE, Scopus, and Web of Science were screened for a comprehensive literature review from 1990 to 2020 regarding series of patients treated for CS-dAVF with endovascular approaches. We performed a proportion meta-analysis estimating the pooled rates of each outcome also including data of patients treated in our center. Results A total of 22 studies reporting 1043 patients and 1066 procedures were included. Chemosis was reported in 559 out of 1043 patients (45.9%), proptosis in 498 (41.5%), and ophthalmoplegia in 344 (23.5%). A transvenous embolization was preferred in 753 cases (63.2%) and coils were used in 712 out of 1066 procedures (57.8%). Overall, 85% (95% confidence interval, CI 69.5–96.1%) of patients had a complete resolution of symptoms, while complications occurred in 7.75% (95% CI 3.82–12.7%) with minimal permanent deficits (0.15%). The mortality rate was 1 out of 1043 patients (< 0.001). Conclusion A transvenous coiling is the most common endovascular approach for CS-dAVF, achieving a high percent... Continued on ES/IODE ➡️ https://etcse.fr/5mzv ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Endovascular Treatment of Cavernous Sinus Dural Arteriovenous Fistulas. Institutional Series, Systematic Review and Meta-Analysis Abstract: Purpose Endovascular treatment represents the first-line therapy for cavernous sinus dural arteriovenous fistulas (CS-dAVF); however, different approaches and embolic agents as well as occlusion rates, complications and clinical outcomes are reported among the published series. In this study we performed a comprehensive meta-analysis to investigate clinical and radiological outcomes after endovascular treatment of CS-dAVFs. Methods PubMed, Ovid Medline, Ovid EMBASE, Scopus, and Web of Science were screened for a comprehensive literature review from 1990 to 2020 regarding series of patients treated for CS-dAVF with endovascular approaches. We performed a proportion meta-analysis estimating the pooled rates of each outcome also including data of patients treated in our center. Results A total of 22 studies reporting 1043 patients and 1066 procedures were included. Chemosis was reported in 559 out of 1043 patients (45.9%), proptosis in 498 (41.5%), and ophthalmoplegia in 344 (23.5%). A transvenous embolization was preferred in 753 cases (63.2%) and coils were used in 712 out of 1066 procedures (57.8%). Overall, 85% (95% confidence interval, CI 69.5–96.1%) of patients had a complete resolution of symptoms, while complications occurred in 7.75% (95% CI 3.82–12.7%) with minimal permanent deficits (0.15%). The mortality rate was 1 out of 1043 patients (< 0.001). Conclusion A transvenous coiling is the most common endovascular approach for CS-dAVF, achieving a high percent... Continued on ES/IODE ➡️ https://etcse.fr/5mzv ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis.  This approval marks Alfapump as the first active implantable medical device for this condition in the US. Professor H.E. Vargas of the Mayo Clinic expressed the significance of this approval: “The FDA approval of alfapump opens the door to a breakthrough therapeutic option for patients with ascites. This technology not only provides effective treatment but also improves quality of life.” The company’s CEO, Ian Crosbie, also emphasised the milestone’s importance: “Today marks a huge milestone for the liver ascites community. Our vision is to transform the lives of these patients with a solution that allows them to take back their lives.” The Alfapump system is designed to automatically and continuously move ascites from the abdomen to the bladder, eliminating the need for therapeutic paracentesis.  The POSEIDON study showed significant improvements in patient quality of life with the Alfapump system. Sequana Medical plans to launch the Alfapump system commercially in the US in the second half of 2025, targeting liver transplant centers with a specialty sales force.  The company expects a market opportunity exceeding $2 billion by 2025, driven by conditions like NASH/MASH and alcoholic liver disease. Read more: https://lnkd.in/eaZJ7ER5 Stay in touch with all the leading stories, events and opportunities by subscribing to my weekly LinkedIn Newsletter here:  https://bit.ly/3KQs0mD

Ocular Therapeutix Inc hosted an Investor Day where it highlighted clinical development progress with Axpaxli for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR) and updated its corporate strategy. During its Investor Day, the company noted the SOL-1 study has 60 study sites active and 151 subjects enrolled in various stages of loading and randomization as of June 7, 2024. The study is being conducted under a Special Protocol Assessment (SPA) with the US FDA. The Company intends to randomize 300 treatment naïve patients in the SOL-1 study, comparing a single implant (450µg) to a single aflibercept injection (2mg) after all patients have received two loading doses of aflibercept. Read More: https://ow.ly/I1QN50SiUCN